Dementia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia), By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors), By Region & Competition, 2020-2030F

Market Report | 2025-03-24 | 186 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License $4500.00
- Multi-User License $5500.00
- Custom Research License $8000.00

Report description:

Global Dementia Drugs Market was valued at USD 14.57 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.87% through 2028. The market is being driven by several factors, including the rising occurrence of target diseases, the introduction of novel and advanced technologies and medications, as well as increased government funding and awareness campaigns for dementia. According to data from the World Health Organization as of September 2022, approximately 55 million individuals across the globe were affected by dementia, with over 60% of them residing in low- and middle-income nations. With the aging population increasing in virtually every country, experts anticipate this number to surge to 78 million by 2030 and a staggering 139 million by 2050. Consequently, the expanding prevalence of dementia on a global scale is anticipated to propel growth within the market. For instance, according to the NCBI, approximately 6.7 million individuals aged 65 and older in the U.S. were living with Alzheimer's disease dementia in 2023. This number is projected to nearly double, reaching around 13.8 million by 2060. Also, the rising government support through funding, policy initiatives, and public awareness campaigns aimed at educating people about Alzheimer's are expected to further drive market growth. These efforts focus on early diagnosis, improved treatment options, and enhanced caregiving support, contributing to increased demand for innovative therapies and healthcare solutions. The growing emphasis on research and public health strategies underscores the urgency of addressing Alzheimer's disease.

Key Market Drivers

Increasing Dementia Prevalence

One of the most prominent factors contributing to the rise in dementia prevalence is the aging global population. As people live longer, the risk of developing dementia increases significantly. The baby boomer generation, which constitutes a substantial portion of the world's population, is now reaching retirement age. This demographic shift results in a larger pool of individuals susceptible to dementia, creating a substantial market for dementia drugs.

According to WHO data published in March 2023, over 55 million people worldwide suffer from dementia, with cases expected to rise to 78 million by 2030 and 139 million by 2050. Each year, approximately 10 million new cases are reported, with higher prevalence in developing countries like China, India, and Brazil. The development of novel dementia treatments is expected to drive market growth. For example, in November 2023, Eisai Co., Ltd. launched Leqembi in the U.S., aiming to have 10,000 prescriptions by March 2024. The drug received FDA approval in July 2023, marking a significant step in dementia treatment.

Advances in healthcare, nutrition, and medical technology have contributed to increased lifespans. While this is a remarkable achievement, it also means that individuals are more likely to live long enough to develop age-related conditions such as dementia. The extended lifespan of the elderly population further fuels the demand for effective dementia treatments.

Key Market Challenges

Complex Pathology and Lack of Cure

Dementia, particularly Alzheimer's disease, is characterized by complex and multifaceted pathology. The exact causes of dementia are not fully understood, making it difficult to develop targeted therapies. Currently, there is no cure for dementia, and many drugs in development have focused on symptom management rather than addressing the root causes of the disease.

Key Market Trends

Disease-Modifying Therapies

One of the most anticipated trends in the dementia drugs market is the development of disease-modifying therapies. Researchers are increasingly focusing on treatments that target the underlying causes of dementia, such as the accumulation of amyloid-beta plaques and tau protein tangles in Alzheimer's disease. Promising drug candidates and clinical trials are offering hope for treatments that can slow down or even halt disease progression.

Key Market Players

- AstraZeneca PLC
- Aurobindo Pharma Limited
- Eli Lilly & Co
- Johnson & Johnson
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
- Zydus Lifesciences Ltd
- Biogen Inc
- GSK PLC
- Merck & Co Inc

Report Scope:

In this report, the Global Dementia Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

- Dementia Drugs Market, By Indications:
  - o Alzheimer's Disease
  - o Lewy Body Dementia
  - o Parkinsons Disease Dementia
  - o Vascular Dementia
- Dementia Drugs Market, By Drug Class:
  - o Cholinesterase Inhibitors
  - o Glutamate Inhibitors
  - o MAO Inhibitors
- Dementia Drugs Market, By Region:

o North America
 United States
 Canada
 Mexico
o Europe
 Germany
 United Kingdom
 France
 Italy
 Spain
o Asia-Pacific
 China
 Japan
 India
 Australia
 South Korea
o South America
 Brazil
 Argentina
 Colombia
o Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
 Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Dementia Drugs Market.
Available Customizations:
Global Dementia Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
-Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Dementia Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia)
5.2.2. By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Product Market Map
5.3.1. By Indications
5.3.2. By Drug Class
5.3.3. By Region
6. North America Dementia Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia)
6.2.2. By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors)
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Dementia Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indications
6.3.1.2.2. By Drug Class
6.3.2. Canada Dementia Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indications
6.3.2.2.2. By Drug Class
6.3.3. Mexico Dementia Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indications
6.3.3.2.2. By Drug Class
7. Europe Dementia Drugs Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia)
7.2.2. By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors)
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Dementia Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indications
7.3.1.2.2. By Drug Class
7.3.2. United Kingdom Dementia Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indications
7.3.2.2.2. By Drug Class
7.3.3. France Dementia Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indications
7.3.3.2.2. By Drug Class
7.3.4. Italy Dementia Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indications
7.3.4.2.2. By Drug Class
7.3.5. Spain Dementia Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indications
7.3.5.2.2. By Drug Class
8. Asia-Pacific Dementia Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia)
8.2.2. By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors)
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Dementia Drugs Market Outlook
8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indications
8.3.1.2.2. By Drug Class
8.3.2. Japan Dementia Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indications
8.3.2.2.2. By Drug Class
8.3.3. India Dementia Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indications
8.3.3.2.2. By Drug Class
8.3.4. Australia Dementia Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indications
8.3.4.2.2. By Drug Class
8.3.5. South Korea Dementia Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indications
8.3.5.2.2. By Drug Class
9. South America Dementia Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia)
9.2.2. By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors)
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Dementia Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indications
9.3.1.2.2. By Drug Class
9.3.2. Argentina Dementia Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indications

9.3.2.2.2. By Drug Class
9.3.3. Colombia Dementia Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indications
9.3.3.2.2. By Drug Class
10. Middle East and Africa Dementia Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia)
10.2.2. By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors)
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Dementia Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indications
10.3.1.2.2. By Drug Class
10.3.2. Saudi Arabia Dementia Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indications
10.3.2.2.2. By Drug Class
10.3.3. UAE Dementia Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indications
10.3.3.2.2. By Drug Class
10.3.4. Kuwait Dementia Drugs Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Indications
10.3.4.2.2. By Drug Class
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. AstraZeneca PLC
14.1.1. Business Overview
14.1.2. Product Offerings
14.1.3. Recent Developments
14.1.4. Financials (As Reported)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Aurobindo Pharma Limited
14.3. Eli Lilly & Co
14.4. Johnson & Johnson
14.5. Pfizer Inc
14.6. Teva Pharmaceutical Industries Ltd
14.7. Zydus Lifesciences Ltd
14.8. Biogen Inc
14.9. GSK PLC
14.10.Merck & Co Inc
15. Strategic Recommendations
16. About Us & Disclaimer

Dementia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia), By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors), By Region & Competition, 2020-2030F

Market Report | 2025-03-24 | 186 pages | TechSci Research

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$4500.00
	Multi-User License	$5500.00
	Custom Research License	$8000.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	

Address*		City*	
Zip Code*		Country*	
		Date	2025-05-12
		Signature	